Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RCUS
stocks logo

RCUS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
25.79M
-28.37%
-1.290
+29.03%
31.40M
+12.14%
-1.090
+5.83%
23.90M
-85.06%
-1.050
-7.89%
Estimates Revision
The market is revising Upward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by 107.22%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.69%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.24%
In Past 3 Month
Stock Price
Go Up
up Image
+107.22%
In Past 3 Month
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 25.260
sliders
Low
14.00
Averages
28.38
High
56.00
Current: 25.260
sliders
Low
14.00
Averages
28.38
High
56.00
BofA
Neutral
maintain
$17 -> $26
2025-11-28
Reason
BofA
Price Target
$17 -> $26
2025-11-28
maintain
Neutral
Reason
BofA raised the firm's price target on Arcus Biosciences to $26 from $17 and keeps a Neutral rating on the shares after incorporating Taiho's option of RCC candidate casdatifan in its Arcus model while making "limited adjustments" to its forecasts following the company's Q3 earnings update.
Goldman Sachs
Salveen Richter
Neutral
maintain
$14 -> $16
2025-10-30
Reason
Goldman Sachs
Salveen Richter
Price Target
$14 -> $16
2025-10-30
maintain
Neutral
Reason
Goldman Sachs analyst Salveen Richter raised the firm's price target on Arcus Biosciences (RCUS) to $16 from $14 and keeps a Neutral rating on the shares. Arcus reported Q3 EPS and provided updates and timelines for its programs, including casdatifan in clear-cell renal cell carcinoma, where the Phase 3 study in the post-IO setting continues to enroll, but enrollment has been paused for the Phase 1b/3 1L trial to assess the combination regimen's safety profile, the analyst tells investors in a research note. Goldman continues to view cas's profile as differentiated vs. Merck's (MRK) competitor drug Welireg.
Wedbush
Outperform
maintain
$33 -> $35
2025-10-29
Reason
Wedbush
Price Target
$33 -> $35
2025-10-29
maintain
Outperform
Reason
Wedbush raised the firm's price target on Arcus Biosciences to $35 from $33 and keeps an Outperform rating on the shares following third quarter results. Recently updated data for casdatifan as monotherapy in heavily pretreated clear cell renal cell carcinoma patients showed a modified progression-free survival of 12.2 months at a median follow-up of 15.2 months, and an objective response rate of 31%, which Wedbush believes, along with promising cabo combination data presented at ASCO 2025, strongly differentiates its profile compared to belzutifan, the firm told investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$24 -> $28
2025-10-29
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$24 -> $28
2025-10-29
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Arcus Biosciences to $28 from $24 and keeps a Buy rating on the shares following the Q3 report. The firm says the LITESPARK-022 trial shows potential for HIF2 alpha inhibitors to be used in early treatment of renal cell carcinoma.
Citi
Buy
maintain
$54 -> $56
2025-10-29
Reason
Citi
Price Target
$54 -> $56
2025-10-29
maintain
Buy
Reason
Citi raised the firm's price target on Arcus Biosciences to $56 from $54 and keeps a Buy rating on the shares.
Barclays
Peter Lawson
Buy
Maintains
$29 → $14
2025-04-23
Reason
Barclays
Peter Lawson
Price Target
$29 → $14
2025-04-23
Maintains
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -5.85, compared to its 5-year average forward P/E of -6.38. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.38
Current PE
-5.85
Overvalued PE
-2.30
Undervalued PE
-10.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.95
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.88
Undervalued EV/EBITDA
-8.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
14.09
Current PS
0.00
Overvalued PS
20.85
Undervalued PS
7.33
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 186.42% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RCUS News & Events

Events Timeline

(ET)
2025-10-31
07:34:15
Arcus Biosciences Prices 13.7M Share Spot Secondary at $18.25
select
2025-10-30 (ET)
2025-10-30
17:24:52
Arcus Biosciences Plans Secondary Offering; Price Range Set at $18.25-$18.75
select
2025-10-30
16:03:48
Arcus Biosciences Reveals Common Stock Offering, Amount Not Disclosed
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-29NASDAQ.COM
B of A Securities Upholds Neutral Rating for Arcus Biosciences (RCUS)

  • Analyst Recommendation: B of A Securities has maintained a Neutral recommendation for Arcus Biosciences (NYSE:RCUS) as of November 28, 2025, with an average one-year price target of $33.01/share, indicating a potential upside of 26.53% from its current price of $26.09/share.

  • Financial Projections: The projected annual revenue for Arcus Biosciences is $188 million, reflecting a decrease of 21.63%, while the projected non-GAAP EPS is -4.02.

  • Institutional Ownership Trends: There are 414 funds reporting positions in Arcus Biosciences, with a slight decrease of 2.59% in ownership over the last quarter, although total shares owned by institutions increased by 0.75% to 111,500K shares.

  • Shareholder Activity: Gilead Sciences remains the largest shareholder with 25.40% ownership, while Point72 Asset Management and IJR - iShares Core S&P Small-Cap ETF have reduced their holdings, while Woodline Partners increased theirs by 40.31% over the last quarter.

[object Object]
Preview
6.0
11-29Benzinga
B of A Securities Keeps Neutral Rating on Arcus Biosciences and Increases Price Target to $26

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

[object Object]
Preview
9.5
11-25Benzinga
Semtech Reports Mixed Q3 Results, Alongside Zhihu, Nvidia, and Other Major Stocks Declining in Tuesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.1% on Tuesday morning.

  • Semtech Corp Financial Results: Semtech Corp's shares fell 7.2% in pre-market trading after reporting mixed third-quarter results, with revenue of $267 million missing estimates but adjusted earnings of 48 cents per share exceeding expectations.

  • Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Arcus Biosciences (-6.7%), Nanobiotix (-6.2%), and Zhihu Inc (-5.2%).

  • Notable Stock Movements: Advanced Micro Devices and NVIDIA saw declines of 3.8% and 4.2%, respectively, following previous gains, indicating a broader trend of falling stock prices in the tech sector.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Arcus Biosciences Inc (RCUS) stock price today?

The current price of RCUS is 25.26 USD — it has decreased -1.44 % in the last trading day.

arrow icon

What is Arcus Biosciences Inc (RCUS)'s business?

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

arrow icon

What is the price predicton of RCUS Stock?

Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Arcus Biosciences Inc (RCUS)'s revenue for the last quarter?

Arcus Biosciences Inc revenue for the last quarter amounts to 26.00M USD, decreased -45.83 % YoY.

arrow icon

What is Arcus Biosciences Inc (RCUS)'s earnings per share (EPS) for the last quarter?

Arcus Biosciences Inc. EPS for the last quarter amounts to -1.27 USD, increased 25.74 % YoY.

arrow icon

What changes have occurred in the market's expectations for Arcus Biosciences Inc (RCUS)'s fundamentals?

The market is revising Upward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by 107.22%.
arrow icon

How many employees does Arcus Biosciences Inc (RCUS). have?

Arcus Biosciences Inc (RCUS) has 627 emplpoyees as of December 05 2025.

arrow icon

What is Arcus Biosciences Inc (RCUS) market cap?

Today RCUS has the market capitalization of 3.07B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free